In The Lancet, Ronald van Vollenhoven and colleagues report a positive multicentre double-blind phase 2 randomised, placebo-controlled trial with ustekinumab, an anti-interleukin-12/23 (IL-12/23) monoclonal antibody, in 102 patients aged 18–75 years with active systemic lupus erythematosus (93 women and nine men).